発表論文 (2003～)

1. Igawa Y., Fujiwara S., Ohura K., Hirokawa T., Nishizawa Y., Uehara S., Uno Y., Imai T., Differences in Intestinal Hydrolytic Activities between Cynomolgus Monkeys and Humans: Evaluation of Substrate Specificities Using Recombinant Carboxylesterase 2 Isozymes.
   Mol. Pharm. 13(9):3176-3186 (2016).

2. Imai T., Ariyoshi S., Ohura K., Sawada T., Nakada Y., Expression of Carboxylesterase Isozymes and Their Role in the Behaviour of a Fexofenadine Prodrug in Rat Skin.
   J. Pharm. Sci. 105(2):714-721 (2016).

3. Ohura K., Nakada Y., Kotani S., Imai T., Design of Fexofenadine Prodrugs Based on Tissue-Specific Esterase Activity and Their Dissimilar Recognition by P-Glycoprotein.
   J. Pharm. Sci. 104(9):3076-3083 (2015).

4. Uno Y., Hosokawa M., Imai T., Isolation and characterization of arylacetamide deacetylase in cynomolgus macaques.
   J. Vet. Med. Sci.77(6):721-724 (2015).

5. Matsusaki M., Hikimoto D., Nishiguchi A., Kadowaki K., Ohura K., Imai T., Akashi M., 3D-Fibroblast Tissues Constructed by a Cell-Coat Technology Enhance Tight-Junction Formation of Human Colon Epithelial Cells.
   Biochem. Biophys. Res. Commun. 457(3):363-369 (2014).

6. Ohura K, Tasaka K, Hashimoto M, Imai T., Distinct patterns of aging effects on the expression and activity of carboxylesterases in rat liver and intestine.
   Drug Metab. Dispos. 42(2):264-273 (2014).

7. Ustün-Aytekin O, Gürhan ID, Ohura K, Imai T, Ongen G., Monitoring of the effects of transfection with baculovirus on Sf9 cell line and expression of human dipeptidyl peptidase IV.
   Cytotechnology 66(1):159-168 (2014).

8. Imai T, Takase Y, Iwase H, Hashimoto M., Involvement of Carboxylesterase in Hydrolysis of Propranolol Prodrug during Permeation across Rat Skin.
   Pharmaceutics 5(3): 371-84 (2013).

9. Bahar FG, and Imai T., Aspirin hydrolysis in human and experimental animal plasmas and the effect of metal cations on their hydrolase activities.
   Drug Metab. Dispos. 41(7):1450-1456 (2013).

10. Koyama K, Nakai D, Takahashi M, Nakai N, Kobayashi N, Imai T, and Izumi T., Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
    Drug Metab. Dispos. 41(1): 180-187 (2013).

11. Bahar FG, Ohura K, Ogihara T, and Imai T., Species difference of esterase expression and hydrolase activity in plasma
    J. Pharm. Sci. 101(10): 3979-3988 (2012).

12. Ohura K, Soejima T, Nogata R, Adachi Y, Ninomiya S, and Imai T., Effect of intestinal first-pass hydrolysis on the oral bioavailability of an ester prodrug of fexofenadine
    J. Pharm. Sci. 101(9): 3264-3274 (2012).

13. Imai T., Prodrug approach in current drug discovery.
    Drug Metab. Pharmacokinet. 26(4): 307-308 (2011).

14. Zhang JS., Kadowaki D., Nonoguchi H., Hirata S., Seo H., Imai T., Suenaga A., Giam Chuang V.T., Otagiri M., Toxicodynamic evaluation of a cisplatin-chondroitin sulfate complex using a perfused kidney and human proximal tubular cells.
    Ren. Fail. 33(6): 609-614 (2011).

15. Ohura K., Nozawa T., Murakami K., and Imai T., Evaluation of transport mechanism of prodrugs and parent drugs formed by intracellular metabolism in Caco-2 cells with modified carboxylesterase activity: Temocapril as a model case
    J. Pharm. Sci. 100(9): 3985-3994 (2011).

16. Nozawa T., and Imai T., Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity
    Drug Metab. Dispos. 39 (7): 1263-1269 (2011).

17. Zhang JS., Anraku M., Kadowaki D., Imai T., Suenaga A., Odani A., and Otagiri M., Spectroscopic studies of interactions of chondroitin sulfates with cisplatin
    Carbohydr. Res. 346(5): 631-637 (2011).

18. Holmes RS., Wright MW., Laulederkind SJ., Cox LA., Hosokawa M., Imai T., Ishibashi S., Lehner R., Miyazaki M., Perkins EJ., Potter PM., Redinbo MR., Robert J., Satoh T., Yamashita T., Yan B., Yokoi T., Zechner R., and Maltais LJ., Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins
    Mamm. Genome 21(9-10): 427-441 (2010).

19. Anraku M., Arahira M., Mady FM., Khaled KA., Yamasaki K., Seo H., Imai T., and Otagiri M., Enhancement of dissolution and bioavailability of flurbiprofen by low molecular weight chitosans
    Pharmazie. 65(7):461-466 (2010).

20. Imai T., Carboxylesterase- Targets for drug and prodrug efficacy and pharmacokinetics.
    Highlights ? A PGx Focus Group Newsletter, AAPS 2(2): 2-4 (2010).

21. Ohura K., Sakamoto H., Ninomiya S., and Imai T., Development of a novel system for estimating human intestinal absorption using Caco-2 cells in the absence of esterase activity
    Drug Metab. Dispos. 38(2): 323-331 (2010).

22. Otagiri M., Kragh-Hansen U., and Imai T., Albumins with new functions and clinical applications
    Drug Metab. Pharmacokinet. 24(4): 285-286 (2009).

23. Imoto M., Azuma H., Yamamoto I., Otagiri M., and Imai T., Permeability of 5-fluorouracil and its prodrugs in Caco-2 cell monolayers: evidence for shift from paracellular to transcellular transport by prodrug formation
    J. Drug Deliv. Sci. Technol. 19(1): 37-41 (2009).

24. Taketani M., Shii M., Ohura K., Ninomiya S., and Imai T., Carboxylesterase in the liver and small intestine of experimental animals and human
    Life Sci. 81(11): 924-932 (2007).

25. Koji Yokoo, Akinobu Hamada, Hiroshi Watanabe, Takanobu Matsuzaki, Tomoyuki Imai, Hiromi Fujimoto, Kengo Masa, Teruko Imai, Hideyuki Saito, Involvement of Up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats
    Drug Metab. Dispos. 35(9): 1511-1517 (2007).

26. K. Masaki, M. Hashimoto and T. Imai, Intestinal first-pass metabolism via carboxylesterase in rat jejunum and ileum
    Drug Metab. Dispos. 35(7): 924-932 (2007) in press.

27. T. Imai , M. Taketani, M. Shii, M. Hosokawa and K. Chiba, Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in the human liver and small intestine
    Drug Metab. Dispos. 34(10): 1734-1741 (2006).

28. T. Imai , Human carboxylesterase isozymes: catalytic characteristics and their use for drug design.
    Drug Metab. Pharmacokinet. 21(3): 173-185 (2006).

29. K. Masaki, M. Taketani and T. Imai , First-Pass Hydrolysis of a Propranolol Ester Derivative in Rat Small Intestine
    Drug Metab. Dispos. 34(3): 398-404 (2006).

30. Y. Morioka, M. Nishimura, T. Imai , S. Suzuki, M. Harada, T. Satoh and S. Naito, Assessment of Induction of Cytochrome P450 by NO-1886 (Ibrolipim), a Lipoprotein Lipase-Promoting Agent, in Primary Cultures of Human Hepatocytes and in Female Rat Liver.
    Drug Metab. Pharmacokinet. 21(1): 19-28 (2006).

31. T. Imai , M. Imoto, H. Sakamoto and M. Hashimoto, Identification of Esterases Expressed in Caco-2 Cells and Effects of Their Hydrolyzing Activity in Predicting Human Intestinal Absorption.
    Drug Metab. Dispos. 33(8): 1185-1190 (2005).

32. Q. Li, Y. Kato, Y. Sai, T. Imai and A. Tsuji, Multidrug Resistance-Associated Protein 1 Functions as an Efflux Pump of Xenobioilcs in the Skin.
    Pharm. Res. 22(6): 842-846 (2005).

33. T. Imai , M. Sakai, H. Ohtake, H. Azuma and M. Otagiri, Absorption Enhancing Effect of Glycyrrhizin Induced in the Presence of Capric Acid.
    Int. J. Pharm. 294(1-2): 11-21 (2005).

34. M. Nishimura, T. Imai , Y. Morioka, S. Kuribayashi, T. Kamataki and S.Naito, Effects of NO-1886 (Ibrolipim), a Lipoprotein Lipase-Promoting Agent, on Gene Induction of Cytochrome P450s, Carboxylesterases, and Sulfotransferases in Primary Cultures of Human Hepatocytes.
    Drug Metab. Pharmacokinet. 19(6): 422-429(2004).

35. Y. Morioka, M. Harada, T. Imai and S. Naito
    Pharmacokinetics and metabolism of No-1886, a lipoprotein lipase-promoting agent, in cynomolgus monkey
    Xenobiotica (33): 1247-1260 (2003).

36. Imai , Y. Yoshigae, M. Hosokawa, K Chiba , and M. Otagiri
    Evidence for the involvement of a pulmonary first-pass effect via carboxylesterase in the disposition of a propranolol ester derivative after intravenous administration
    J. Pharmacol. Exp. Ther (307): 1234-1242 (2003).

37. Imai , T. Nomura, and M. Otagiri
    Probenecid-induced changes in the clearance of pranoprofen enantiomers
    Chirality (15): 318-323 (2003).

38. T. Imai , T. Nomura, M. Aso, M. Otagiri
    Enantiospecific disposition of pranoprofen in beagle dogs and rats
    Chirality (15): 312-317 (2003).